These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 35760470)

  • 21. Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma.
    Yang Y; Psutka SP; Parikh AB; Li M; Collier K; Miah A; Mori SV; Hinkley M; Tykodi SS; Hall E; Thompson JA; Yin M
    Cancer Med; 2022 Aug; 11(16):3106-3114. PubMed ID: 35304832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of Thromboembolism in Patients Receiving Immunotherapy-Based Combinations as Front-Line Therapy for Metastatic Renal Cell Carcinoma.
    Schuster J; Sheng IY; Reddy CA; Khorana AA; Nizam A; Gupta S; Gilligan T; Wee CE; Sussman TA; Bonham A; Maroli K; Martin A; Ornstein MC
    Clin Genitourin Cancer; 2024 Apr; 22(2):92-97. PubMed ID: 37932205
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Not Available].
    Borchiellini D
    Bull Cancer; 2018 Dec; 105 Suppl 3():S242-S254. PubMed ID: 30595153
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First-line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the effectiveness using real-world data.
    Ishihara H; Omae K; Nemoto Y; Ishiyama R; Tachibana H; Nishimura K; Ikeda T; Kobari Y; Fukuda H; Yoshida K; Shimmura H; Hashimoto Y; Iizuka J; Kondo T; Takagi T
    Int J Clin Oncol; 2024 Apr; 29(4):473-480. PubMed ID: 38345708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A U.S. Food and Drug Administration-pooled Analysis of Frontline Combination Treatment Survival Benefits by Risk Groups in Metastatic Renal Cell Carcinoma.
    Lee D; Gittleman H; Weinstock C; Suzman D; Bloomquist E; Agrawal S; Brave M; Brewer J; Fallah J; Singh H; Tang S; Ibrahim A; Pazdur R; Beaver JA; Amiri-Kordestani L
    Eur Urol; 2023 Oct; 84(4):373-378. PubMed ID: 37271635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of Provider Preferences in First-Line Metastatic Renal Cell Carcinoma: Comparison Between Dual Immunotherapy vs. Immunotherapy/Tyrosine Kinase Inhibitors.
    Chablani PV; Karrison T; Stadler WM
    Clin Genitourin Cancer; 2022 Dec; 20(6):510-514. PubMed ID: 35869002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
    Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
    Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium.
    Dudani S; Graham J; Wells JC; Bakouny Z; Pal SK; Dizman N; Donskov F; Porta C; de Velasco G; Hansen A; Iafolla M; Beuselinck B; Vaishampayan UN; Wood LA; Liow E; Yan F; Yuasa T; Bjarnason GA; Choueiri TK; Heng DYC
    Eur Urol; 2019 Dec; 76(6):861-867. PubMed ID: 31445844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cabozantinib and nivolumab as first-line treatment in advanced renal cell carcinoma.
    Vitale MG; Nasso C; Oltrecolli M; Baldessari C; Fanelli M; Dominici M; Sabbatini R
    Expert Rev Anticancer Ther; 2021 Nov; 21(11):1183-1192. PubMed ID: 34424125
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma.
    Zarrabi KK; Handorf E; Miron B; Zibelman MR; Anari F; Ghatalia P; Plimack ER; Geynisman DM
    Oncologist; 2023 Feb; 28(2):157-164. PubMed ID: 36200791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?
    Vano YA; Ladoire S; Elaidi R; Dermeche S; Eymard JC; Falkowski S; Gross-Goupil M; Malouf G; Narciso B; Sajous C; Tartas S; Voog E; Ravaud A
    Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771710
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Developments in personalized therapy for metastatic renal cell carcinoma.
    Fujiwara R; Kageyama S; Yuasa T
    Expert Rev Anticancer Ther; 2022 Jun; 22(6):647-655. PubMed ID: 35531636
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214.
    Escudier B; Motzer RJ; Tannir NM; Porta C; Tomita Y; Maurer MA; McHenry MB; Rini BI
    Eur Urol; 2020 Apr; 77(4):449-453. PubMed ID: 31732098
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective.
    Engel Ayer Botrel T; Datz Abadi M; Chabrol Haas L; da Veiga CRP; de Vasconcelos Ferreira D; Jardim DL
    J Med Econ; 2021; 24(1):291-298. PubMed ID: 33538203
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of First-Line Anti-PD-1-Based Combination Therapies in Metastatic Renal-Cell Carcinoma: Real-World Experiences from a Retrospective, Multi-Institutional Cohort.
    Hoeh B; Schmucker P; Klümper N; Hahn O; Zeuschner P; Banek S; Karakiewicz PI; Ellinger J; Heinzelbecker J; Hölzel M; Strauß A; Zengerling F; Mattigk A; Kalogirou C
    Urol Int; 2022; 106(11):1150-1157. PubMed ID: 35158357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes With Combination Pembrolizumab and Axitinib in Second and Further Line Treatment of Metastatic Renal Cell Carcinoma.
    Dizman N; Austin M; Considine B; Jessel S; Schoenfeld D; Merl MY; Hurwitz M; Sznol M; Kluger H
    Clin Genitourin Cancer; 2023 Apr; 21(2):221-229. PubMed ID: 36681606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SEOM SOGUG clinical guideline for treatment of kidney cancer (2022).
    Méndez-Vidal MJ; Lázaro Quintela M; Lainez-Milagro N; Perez-Valderrama B; Suárez Rodriguez C; Arranz Arija JÁ; Peláez Fernández I; Gallardo Díaz E; Lambea Sorrosal J; González-Del-Alba A
    Clin Transl Oncol; 2023 Sep; 25(9):2732-2748. PubMed ID: 37556095
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combinations of Anti-Angiogenic Agents and Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Best Option?
    Granet-Vaissiere E; Lefort F; Domblides C; Larroquette M; Ravaud A; Bernhard JC; Gross-Goupil M
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831392
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current and emerging first-line systemic therapies in metastatic clear-cell renal cell carcinoma.
    Tegos T; Tegos K; Dimitriadou A; Dimitriadis G
    J BUON; 2019; 24(4):1340-1353. PubMed ID: 31646776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. First-Line Systemic Therapy for Metastatic Clear-Cell Renal Cell Carcinoma: Critical Appraisal of Emerging Options.
    Loo V; Salgia M; Bergerot P; Philip EJ; Pal SK
    Target Oncol; 2019 Dec; 14(6):639-645. PubMed ID: 31595385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.